• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

May-Hegglin异常中编码非肌肉肌球蛋白重链A的MYH9突变。

Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.

作者信息

Kelley M J, Jawien W, Ortel T L, Korczak J F

机构信息

Department of Medicine, Duke University, Durham, North Carolina, USA.

出版信息

Nat Genet. 2000 Sep;26(1):106-8. doi: 10.1038/79069.

DOI:10.1038/79069
PMID:10973260
Abstract

May-Hegglin anomaly (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia, giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal, suggesting a defect in megakaryocyte fragmentation. The disorder has been linked to chromosome 22q12-13. Here we screen a candidate gene in this region, encoding non-muscle myosin heavy chain A (MYH9), for mutations in ten families. In each family, we identified one of three sequence variants within either the -helical coiled coil or the tailpiece domain that co-segregated with disease status. The E1841K mutation was found in 5 families and occurs at a conserved site in the rod domain. This mutation was not found in 40 normal individuals. Four families had a nonsense mutation that resulted in truncation of most of the tailpiece. One family had a T1155I mutation present in an affected mother and daughter, but not in the mother's parents, thus representing a new mutation. Among the 30 affected individuals, 21 unaffected individuals and 13 spouses in the 10 families, there was correlation of a variant of MYH9 with the presence of MHA. The identification of MYH9 as the disease gene for MHA establishes the pathogenesis of the disorder, should provide further insight into the processes of normal platelet formation and may facilitate identification of the genetic basis of related disorders.

摘要

May-Hegglin异常(MHA)是一种常染色体显性遗传性大血小板减少症,其发病机制不明,特征为血小板减少、巨大血小板和白细胞包涵体。研究表明血小板结构和功能正常,提示巨核细胞碎裂存在缺陷。该疾病与22号染色体q12 - 13区域相关。在此,我们在该区域筛选了一个编码非肌肉肌球蛋白重链A(MYH9)的候选基因,以检测十个家系中的突变情况。在每个家系中,我们在α - 螺旋卷曲螺旋结构域或尾段结构域内鉴定出三个序列变异之一,这些变异与疾病状态共分离。E1841K突变在5个家系中被发现,发生在杆状结构域的一个保守位点。在40名正常个体中未发现该突变。四个家系存在无义突变,导致尾段大部分被截断。一个家系中,受影响的母亲和女儿存在T1155I突变,但其母亲的父母中未出现,因此代表一个新的突变。在这10个家系的30名患者、21名未受影响个体和13名配偶中,MYH9的一个变异与MHA的存在相关。将MYH9鉴定为MHA的致病基因确立了该疾病的发病机制,应能为正常血小板形成过程提供进一步的见解,并可能有助于确定相关疾病的遗传基础。

相似文献

1
Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.May-Hegglin异常中编码非肌肉肌球蛋白重链A的MYH9突变。
Nat Genet. 2000 Sep;26(1):106-8. doi: 10.1038/79069.
2
Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.非肌肉肌球蛋白重链IIA突变定义了一系列常染色体显性大血小板减少症:May-Hegglin异常以及Fechtner、Sebastian、Epstein和Alport样综合征。
Am J Hum Genet. 2001 Nov;69(5):1033-45. doi: 10.1086/324267. Epub 2001 Oct 4.
3
Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium.MYH9基因的突变会导致May-Hegglin异常以及Fechtner和Sebastian综合征。May-Heggllin/Fechtner综合征研究联盟。
Nat Genet. 2000 Sep;26(1):103-5. doi: 10.1038/79063.
4
Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions.常染色体显性遗传性大血小板减少伴白细胞包涵体中六个新的MYH9突变的鉴定及基因型-表型关系
J Hum Genet. 2001;46(12):722-9. doi: 10.1007/s100380170007.
5
Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome).NMMHC-A基因的突变会导致常染色体显性遗传性大血小板减少症并伴有白细胞包涵体(May-Hegglin异常/塞巴斯蒂安综合征)。
Blood. 2001 Feb 15;97(4):1147-9. doi: 10.1182/blood.v97.4.1147.
6
Genotype-phenotype correlation in MYH9-related thrombocytopenia.MYH9相关血小板减少症的基因型-表型相关性
Br J Haematol. 2005 Aug;130(4):620-7. doi: 10.1111/j.1365-2141.2005.05658.x.
7
Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome.天冬酰胺酸1424位点突变的肌球蛋白重链9(MYH9)会产生一种不稳定蛋白质,该蛋白质与May-Hegglin异常/Fechtner综合征的表型有关。
Blood. 2003 Jul 15;102(2):529-34. doi: 10.1182/blood-2002-09-2783. Epub 2003 Mar 20.
8
[May-Hegglin anomaly--from genome research to clinical laboratory].[迈-赫二氏异常——从基因组研究到临床实验室]
Rinsho Byori. 2003 Sep;51(9):898-904.
9
Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene.爱泼斯坦综合征:另一种由非肌肉肌球蛋白重链9基因突变引起的肾脏疾病。
Hum Genet. 2002 Feb;110(2):182-6. doi: 10.1007/s00439-001-0659-1. Epub 2001 Dec 14.
10
MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.MYH9 相关性血小板减少症:四种新的变异影响非肌肉肌球蛋白重链 IIA 的尾部结构,与该疾病的轻度临床演变相关。
Hamostaseologie. 2019 Feb;39(1):87-94. doi: 10.1055/s-0038-1645840. Epub 2018 Jul 11.

引用本文的文献

1
Molecular Control of Non-Muscle Myosin II-A Aggregation and Intracellular Dynamics by motor- or tail-specific Mutations.通过运动蛋白或尾部特异性突变对非肌肉肌球蛋白II-A聚集和细胞内动力学的分子控制
bioRxiv. 2025 May 21:2025.05.20.654665. doi: 10.1101/2025.05.20.654665.
2
myh9b is a critical non-muscle myosin II encoding gene that interacts with myh9a and myh10 during zebrafish development in both compensatory and redundant pathways.myh9b是一个关键的非肌肉肌球蛋白II编码基因,在斑马鱼发育过程中,它在补偿和冗余途径中与myh9a和myh10相互作用。
G3 (Bethesda). 2025 Jan 8;15(1). doi: 10.1093/g3journal/jkae260.
3
Non-Muscle Myosin II A: Friend or Foe in Cancer?
非肌肉肌球蛋白 IIA:癌症的朋友还是敌人?
Int J Mol Sci. 2024 Aug 30;25(17):9435. doi: 10.3390/ijms25179435.
4
A Case of Myosin Heavy Chain 9-Related Disorder Following Splenectomy Due to Misdiagnosis of Idiopathic Thrombocytopenic Purpura.一例因特发性血小板减少性紫癜误诊行脾切除术后发生的肌球蛋白重链9相关疾病。
Cureus. 2024 Feb 27;16(2):e55064. doi: 10.7759/cureus.55064. eCollection 2024 Feb.
5
Contractility defects hinder glycoprotein VI-mediated platelet activation and affect platelet functions beyond clot contraction.收缩性缺陷阻碍糖蛋白VI介导的血小板活化,并影响除凝块收缩之外的血小板功能。
Res Pract Thromb Haemost. 2024 Jan 22;8(1):102322. doi: 10.1016/j.rpth.2024.102322. eCollection 2024 Jan.
6
Platelet formation and activation are influenced by neuronal guidance proteins.血小板的形成和激活受神经元导向蛋白的影响。
Front Immunol. 2023 Jun 15;14:1206906. doi: 10.3389/fimmu.2023.1206906. eCollection 2023.
7
Macrothrombocytopenia of Takenouchi-Kosaki syndrome is ameliorated by CDC42 specific- and lipidation inhibitors in MEG-01 cells.特努奇-小笠原综合征的巨血小板减少症可被 MEG-01 细胞中 CDC42 特异性和脂化抑制剂改善。
Sci Rep. 2021 Sep 9;11(1):17990. doi: 10.1038/s41598-021-97478-y.
8
R702C is associated with erythroid abnormality with splenomegaly in mice.R702C与小鼠红细胞异常伴脾肿大有关。
Nagoya J Med Sci. 2021 Feb;83(1):75-86. doi: 10.18999/nagjms.83.1.75.
9
Non-Muscle Myosin 2A (NM2A): Structure, Regulation and Function.非肌肉肌球蛋白 2A(NM2A):结构、调节和功能。
Cells. 2020 Jul 1;9(7):1590. doi: 10.3390/cells9071590.
10
Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia.用于治疗遗传性血小板减少症的血小板生成素受体激动剂。
Haematologica. 2020 Mar;105(3):536-538. doi: 10.3324/haematol.2019.241786.